Clinical Trial Update: Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates sacituzumab tirumotecan plus bevacizumab in advanced EGFR-mutant nonsquamous non-small cell lung cancer with brain metastases after…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Sacituzumab Tirumotecan (Sac-TMT)

Snippet

Sponsor: Li-kun Chen | Conditions: Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING